# Section 1: Company Overview

## S1.1: Basic Information

| Field | Value |
| :---- | :---- |
| Company Name | Q & M Dental Group (Singapore) Limited |
| Establishment Date | January 7, 2008 |
| Headquarters Location | Singapore, Singapore |


## S1.2 : Core Competencies

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Innovation Advantages | The Company leverages AI and digital transformation through its associate EM2AI, which has secured medical device licenses in multiple Southeast Asian countries and deploys AI-powered dental charting using OPG and intra-oral cameras across clinics. The proprietary Q & M App integrates dental health reports directly to patients, supporting personalized treatment plans. The Q & M College of Dentistry, accredited with EduTrust Provisional Certification, enhances workforce capabilities by providing AI training and continuous education to dental professionals. | The Company has made early investments in Artificial Intelligence (AI) through its 49% ownership in EM2AI, which has developed AI X-Ray Dental Pathologies Detection, Automated Dental Charting (ADC) systems, and a Dental Health Report integrated with the Q&M mobile application. EM2AI is rolling out an AI Guided Clinical Decision Support System (GCDSS) designed to enhance diagnostic accuracy and treatment planning by minimizing biases, supporting ethical dentistry. The Group also utilizes cloud-based Integrated Dental Management System (EM2Clinic) and pursues continuous R&D in PCR tests for infectious diseases and cancer through its medical laboratory division (Acumen). |
| Product Advantages | The Company operates a broad portfolio of dental services across 106 clinics in Singapore and 38 in Malaysia, including premium clinics such as Azure Dental. Its service offerings encompass a wide range of dental and medical services, including AI-driven diagnostics, aesthetic dentistry, orthodontics, oral surgery, and preventive care. The integration of AI solutions via EM2AI and the Q & M App enhances the suitability and personalization of dental care across its regional footprint. | The Company operates a broad portfolio of dental clinics, including the first private-sector Free Dental Clinic in Singapore, staffed by volunteer dentists and capable of serving up to 1,400 patients annually. It offers AI-empowered dental healthcare solutions via EM2AI's SaaS platform, enabling personalized and ethical treatment plans. The Group also provides PCR testing services and is expanding its diagnostic product portfolio internationally. |
| Brand Recognition | The Company is positioned as a leading integrated dental healthcare provider in Southeast Asia, with long-term relationships supported by its Free Dental Clinic and community outreach programs. It maintains strong stakeholder engagement through regular communication with shareholders and the public, and its brand is underpinned by core values derived from Confucian teachings emphasizing ethics and respect. The Company is recognized for its commitment to ethical, patient-focused care and is expanding its regional presence through strategic partnerships and acquisitions. | The Company is recognized as a leading private dental healthcare group in the region, with a strong commitment to ethical and patient-centric care embodied in its Dentistry 3.0 approach. It maintains long-term relationships with community partners and stakeholders through initiatives such as the Free Dental Clinic, collaborations with migrant worker assistance organizations, and the 'Change for Charity' program. The Board emphasizes transparency, accountability, and stakeholder engagement to uphold the Company's reputation. |
| Reputation Ratings | The Company complies with the Mainboard Rules and Global Reporting Initiative (GRI) Sustainability Reporting Standards, publishing its eighth annual sustainability report for FY2024. It demonstrates adherence to Environmental, Social, and Governance (ESG) principles through initiatives such as ethical sourcing, resource efficiency, community outreach, and environmental programs like tree planting. The Company maintains robust corporate governance practices, including risk management, internal controls, and a whistle-blowing policy, with oversight by the Board and independent auditors. | The Company complies with the Mainboard Rules and Global Reporting Initiative (GRI) Sustainability Reporting Standards, publishing its sustainability report for the seventh consecutive year. It adheres to the Code of Corporate Governance 2018 and maintains high standards of corporate governance, including regular risk management reviews and ethical business practices. The Company has no reported legal or regulatory breaches involving its directors and maintains policies to prevent insider trading and ensure shareholder rights. |


## S1.3 : Mission & Vision

| Field | Value |
| :---- | :---- |
| Mission Statement | 以可持续的方式提供牙科服务 |
| Vision Statement | 成为区域内牙科医疗领域的领导者 |
| Core Values | Loyalty (忠), Truthfulness (信), Respect (礼), Righteousness (义), Integrity (廉) |


# Section 2: Financial Performance

## S2.1: Income Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Revenue | 180,674.0 | 182,723.0 | 181,214.0 | Thousands | SGD |
| Cost of Goods Sold | (22,494.0) | (34,472.0) | N/A | Thousands | SGD |
| Gross Profit | N/A | N/A | N/A | Thousands | SGD |
| Operating Expense | (135,970.0) | (139,731.0) | N/A | Thousands | SGD |
| Operating Income | N/A | N/A | N/A | Thousands | SGD |
| Net Profit | 13,066.0 | 11,073.0 | 11,856.0 | Thousands | SGD |
| Income before income taxes | 14,752.0 | 13,664.0 | 14,277.0 | Thousands | SGD |
| Income tax expense(benefit) | (1,686.0) | (2,591.0) | (2,421.0) | Thousands | SGD |
| Interest Expense | 3,724.0 | 3,985.0 | 2,054.0 | Thousands | SGD |


## S2.2: Balance Sheet

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Total Assets | 247,773.0 | 258,588.0 | 267,412.0 | Thousands | SGD |
| Current Assets | 84,061.0 | 80,592.0 | 81,803.0 | Thousands | SGD |
| Non-Current Assets | 163,712.0 | 177,996.0 | 185,609.0 | Thousands | SGD |
| Total Liabilities | 139,266.0 | 155,677.0 | 165,164.0 | Thousands | SGD |
| Current Liabilities | 28,008.0 | 30,068.0 | 32,912.0 | Thousands | SGD |
| Non-Current Liabilities | 107,456.0 | 122,391.0 | 132,490.0 | Thousands | SGD |
| Shareholders' Equity | 108,507.0 | 102,911.0 | 102,248.0 | Thousands | SGD |
| Retained Earnings | 33,674.0 | 27,841.0 | 24,163.0 | Thousands | SGD |
| Total Equity and Liabilities | 247,773.0 | 258,588.0 | 267,412.0 | Thousands | SGD |
| Inventories | 10,587.0 | 11,812.0 | 11,091.0 | Thousands | SGD |
| Prepaid Expenses | 1,443.0 | 1,464.0 | 2,144.0 | Thousands | SGD |


## S2.3: Cash Flow Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Net Cash Flow from Operations | 40,098.0 | 33,260.0 | 39,746.0 | Thousands | USD |
| Net Cash Flow from Investing | (6,307.0) | (6,955.0) | (10,995.0) | Thousands | USD |
| Net Cash Flow from Financing | (33,442.0) | (32,010.0) | (30,468.0) | Thousands | USD |
| Net Increase/Decrease in Cash | 349.0 | (5,705.0) | (7,913.0) | Thousands | USD |
| Dividends | 8,804.0 | 7,193.0 | 13,152.0 | Thousands | USD |


## S2.4: Key Financial Metrics

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Gross Margin | 112.45% | 118.87% | N/A | Thousands | SGD |
| Operating Margin | N/A | N/A | N/A | Thousands | SGD |
| Net Profit Margin | 7.23% | 6.06% | 6.54% | Thousands | SGD |
| Current Ratio | 300.13% | 268.03% | 248.55% | Thousands | SGD |
| Quick Ratio | 257.18% | 223.88% | 208.34% | Thousands | SGD |
| Interest Coverage | N/A | N/A | N/A | Thousands | SGD |
| Asset Turnover | 71.36% | 69.48% | N/A | Thousands | SGD |
| Debt-to-Equity | 128.35% | 151.27% | 161.53% | Thousands | SGD |
| Return on Equity | 12.36% | 10.79% | N/A | Thousands | SGD |
| Return on Assets | 5.16% | 4.21% | N/A | Thousands | SGD |
| Effective Tax Rate | 11.43% | 18.96% | 16.96% | Thousands | SGD |
| Dividend Payout Ratio | 67.38% | 64.96% | 110.93% | Thousands | SGD |

## S2.5: Operating Performance

| Field | 2024 | 2023 | 2022 |
| :---- | :---- | :---- | :---- |
| Revenue by Product/Service | Core dental business: $173,787, Other businesses: $6,887 | Primary healthcare: $167,765, Dental equipment and supplies distribution: $8,443, Medical laboratory: $6,515 | Primary healthcare: $160,895, Dental equipment and supplies distribution: $11,236, Medical laboratory: $9,083 |
| Revenue by Geographic Region | Singapore: $167,319, Malaysia: $13,355, China: - | Singapore: $171,438, Malaysia: $11,116, China: $169 | Singapore: $167,288, Malaysia: $13,139, China: $787 |


# Section 3: Business Analysis

## S3.1: Profitability Analysis

| Field | Answer |
| :---- | :---- |
| Revenue & Direct-Cost Dynamics | Revenue growth from 2022 to 2023 was positive, increasing from 181,214 to 182,723, representing a growth of approximately 0.83%. However, revenue slightly declined in 2024 to 180,674, indicating a decrease of about 0.57% from 2023. The gross margin showed a decline from 118.87% in 2023 to 112.45% in 2024, suggesting increased costs relative to revenue. In terms of product revenue, the core dental business saw growth from 167,765 in 2023 to 173,787 in 2024, while other businesses decreased from 8,443 in 2023 to 6,887 in 2024. Geographically, revenue from Singapore remained relatively stable, with a slight decrease from 171,438 in 2023 to 167,319 in 2024, while revenue from Malaysia increased from 11,116 to 13,355, and revenue from China dropped significantly from 169 to zero. |
| Operating Efficiency | Operating margin data is not available for the years analyzed. However, the operating income is not provided, making it difficult to assess the operating income versus revenue relationship. Operating expenses decreased from 139,731 in 2023 to 135,970 in 2024, indicating some cost management effectiveness. The net profit margin improved from 6.06% in 2023 to 7.23% in 2024, despite the decline in revenue, suggesting that the company may have effectively managed its costs relative to its income. |
| External & One-Off Impact | The effective tax rate decreased from 18.96% in 2023 to 11.43% in 2024, which positively impacted net profit, increasing it from 11,073 in 2023 to 13,066 in 2024. This significant drop in the tax rate may indicate changes in tax legislation or effective tax planning strategies. There are no non-recurring items or unusual patterns noted in the data provided. External factors affecting profitability include the competitive landscape in the healthcare sector and potential economic conditions impacting consumer spending. |


## S3.2: Financial Performance Summary

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Comprehensive financial health | In 2024, the company's total assets decreased to SGD 247,773,000 from SGD 258,588,000 in 2023, indicating a decline in asset base. However, current assets increased to SGD 84,061,000, reflecting improved liquidity. Total liabilities also decreased to SGD 139,266,000, which is a positive sign of liability management. Shareholders' equity rose to SGD 108,507,000, suggesting a strengthening equity position. The current ratio improved to 300.13%, indicating strong liquidity and a solid capital structure. | In 2023, total assets were SGD 258,588,000, down from SGD 267,412,000 in 2022, indicating a trend of asset reduction. Current assets were SGD 80,592,000, which was an increase from SGD 81,803,000 in 2022, showing some liquidity improvement. Total liabilities decreased to SGD 155,677,000, which is a positive trend in liability management. Shareholders' equity also increased to SGD 102,911,000, reflecting a stable equity position. The current ratio was 268.03%, indicating good liquidity. |
| Profitability and earnings quality | In 2024, revenue decreased slightly to SGD 180,674,000 from SGD 182,723,000 in 2023. However, net profit increased to SGD 13,066,000, resulting in a net profit margin of 7.23%, up from 6.06% in 2023, indicating improved profitability. The return on equity (ROE) improved to 12.36%, suggesting better earnings quality and sustainability. The effective tax rate decreased to 11.43%, which may have contributed to the higher net profit. | In 2023, the company reported revenue of SGD 182,723,000, a slight increase from SGD 181,214,000 in 2022. Net profit was SGD 11,073,000, resulting in a net profit margin of 6.06%, which was lower than the previous year's margin of 6.54%. The return on equity was 10.79%, indicating a stable but slightly declining earnings quality. The effective tax rate was 18.96%, which was higher than in 2022, impacting net profitability. |
| Operational efficiency | In 2024, the company achieved a gross margin of 112.45%, indicating strong operational efficiency despite a decrease in revenue. The asset turnover ratio improved to 71.36%, suggesting better utilization of assets. Net cash from operations increased significantly to SGD 40,098,000 from SGD 33,260,000 in 2023, indicating effective cash flow management. However, operating expenses remained high at SGD 135,970,000, which could be an area for cost management improvement. | In 2023, the company had a gross margin of 118.87%, reflecting strong operational performance. The asset turnover ratio was 69.48%, indicating effective asset utilization. Net cash from operations was SGD 33,260,000, which was an improvement from SGD 39,746,000 in 2022, showing positive cash flow management. Operating expenses were SGD 139,731,000, which suggests a need for better cost management strategies. |
| Financial risk identification and early warning | In 2024, the debt to equity ratio improved to 128.35%, down from 151.27% in 2023, indicating better debt management. The current ratio of 300.13% suggests strong liquidity, reducing financial risk. However, the interest expense remained significant at SGD 3,724,000, which could pose a risk if not managed properly. The effective tax rate decrease to 11.43% may also indicate a favorable tax environment, reducing financial risk. | In 2023, the debt to equity ratio was 151.27%, indicating higher leverage and potential financial risk. The current ratio of 268.03% showed good liquidity, but the interest expense of SGD 3,985,000 was a concern for debt management. The effective tax rate was 18.96%, which could impact net profitability and financial stability if not addressed. |
| Future financial performance projection | Based on 2024 data, the company is likely to focus on improving operational efficiency and cost management to sustain profitability. The increase in net cash from operations suggests a positive cash flow outlook, which may support future investments. The dividend payout increased to SGD 8,804,000, indicating a commitment to returning value to shareholders. Market expansion efforts in Singapore and Malaysia may drive future revenue growth. | In 2023, the company showed signs of stable performance with a focus on maintaining profitability. The net cash from operations was positive, indicating potential for future investments. However, the decline in revenue from certain segments suggests a need for strategic market expansion and diversification. The dividend payout of SGD 7,193,000 reflects a cautious approach to returning value to shareholders while managing financial stability. |


## S3.3: Business Competitiveness

| Field | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Business Model | The company's primary business model is based on the rendering of dental services and the sale of dental goods. Revenue is primarily generated from the core dental business, which includes operating dental clinics and distributing dental supplies and equipment. The company also recognizes profit guarantee income when there is a shortfall between guaranteed profit amounts and actual performance. The target customers for the core dental business are mainly individuals and private dental clinics. | The company primarily operates through the rendering of services and the sale of goods. Revenue is recognized at the point in time when the performance obligation is satisfied, typically upon delivery of goods or completion of services. The main revenue streams include rendering of services (S$171,016,000), sale of goods (S$8,277,000), profit guarantee income (S$2,388,000), and rental income (S$503,000). The target markets include individuals for primary healthcare services, private dental clinics for dental equipment and supplies, and vaccination centers for medical laboratory services. |
| Market Position | The company maintains its position as the largest private dental network in Singapore, operating 106 clinics. In FY2024, the core dental business generated revenue of S$173.8 million, reflecting a marginal growth from the previous year, driven by higher patient volumes and premium service offerings. The company is positioned as a market leader in Singapore and is actively expanding its presence in Southeast Asia, particularly in Malaysia, where it operates 38 clinics. The company has also made strategic acquisitions to enhance its market position. | The company is a market leader in the dental healthcare sector in Singapore, operating the largest network of private dental outlets with 106 clinics. It has a strong presence in Malaysia with 44 dental clinics. The revenue contribution from dental and medical clinics increased by 4% from S$160.9 million in FY2022 to S$167.8 million in FY2023. However, the medical laboratory and dental equipment & supplies segment saw a decrease of 26% in revenue. The company is positioned as a leader in the dental healthcare market, focusing on innovation and expansion into international markets. |


# Section 4: Risk Factors

## S4.1: Risk Factors

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Market Risks | The company faces market risks including demand volatility and competition, particularly in the dental healthcare sector. The decision to cease the medical lab business due to the expiry of a clinical laboratory service license reflects the impact of external market conditions on operational strategy. | The Company faces market risks due to challenging macroeconomic conditions, including geopolitical instability, high interest rates, and inflation, which may affect customer demand and supplier costs. Management has reviewed potential impacts and downside scenarios but identified no material uncertainties regarding operational continuity. |
| Operational Risks | Operational risks include challenges in business continuity and product development, as evidenced by the impairment of non-core assets and the cessation of the medical laboratory business. The company regularly reviews its operational activities to identify and mitigate significant business risks. | Operational risks include challenges in business operations, such as supply chain disruptions and technology system failures. The Company regularly reviews and improves its operational activities to identify and mitigate significant risks. |
| Financial Risks | Financial risks encompass credit risk, liquidity risk, and interest rate risk, with management implementing procedures to monitor and mitigate these risks. The company has established guidelines for financial risk management, including the use of natural hedges and derivatives for hedging purposes. | Financial risks include exposure to foreign currency and interest rate fluctuations, with sensitivity analyses indicating that the impact on post-tax profit is not significant. The Company employs strategies to minimize these risks, including natural hedges and regular monitoring by senior management. |
| Compliance Risks | The company adheres to regulatory compliance and legal requirements, including maintaining proper accounting records and compliance with the Singapore Financial Reporting Standards. The Board oversees compliance with applicable laws and regulations, ensuring that the company meets its statutory obligations. | The Company is subject to various regulatory compliance risks, including adherence to financial reporting standards and corporate governance practices. The Board oversees compliance and has established internal controls to ensure adherence to applicable laws and regulations. |


# Section 5: Corporate Governance

## S5.1: Board Composition
| Name | Position | Total Income |
| :---- | :---- | -----------: |
| Dr Ng Chin Siau | Non-Independent Executive Director/Group Chief Executive Officer | S$788,090 |
| Mdm Ng Sook Hwa | Chief Financial Officer | N/A |

## S5.2: Internal Controls
| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Risk assessment procedures | The Group has put in place documentation on its risk profile which summarises the material risks faced by the Group and the countermeasures in place to manage or mitigate those risks for the review by the Board annually. Risk assessment and evaluation is an essential part of the business planning and monitoring process, considering the likelihood of risks occurring and the risk tolerance accepted by the Group. | The Group has put in place documentation on its risk profile which summarises the material risks faced by the Group and the countermeasures in place to manage or mitigate those risks for the review by the Board annually. The risk assessment and evaluation process is an essential part of the business planning and monitoring process, considering the likelihood of risks occurring and the risk tolerance accepted by the Group. |
| Control activities | The internal controls structure of the Group is designed to provide reasonable assurance against material financial misstatements or loss, safeguarding of assets, maintenance of proper accounting records, and compliance with applicable laws and regulations. The Company prohibits its officers from dealing in the Company's shares on short-term considerations and requires compliance with insider trading provisions. | The internal controls structure of the Group has been designed to provide reasonable assurance against material financial misstatements or loss, safeguarding of assets, maintenance of proper accounting records, and compliance with applicable laws and regulations. Management will continue to review and strengthen the Group's control environment and improve its internal policies and procedures. |
| Monitoring mechanisms | The Company has appointed CLA Global TS Risk Advisory Pte Ltd to perform internal audit reviews, reporting directly to the Audit Committee (AC). The AC reviews the internal audit's plan and ensures that internal auditors have access to all Company documents and personnel. The AC also meets with internal and external auditors without management present at least once a year. | The Company has appointed an independent third party, CLA Global TS Risk Advisory Pte Ltd, to perform internal audit reviews and report significant matters to Management and the Audit Committee (AC). The AC meets at least half-yearly to review the internal control procedures and ensure coordination between the external auditors and Management. |
| Identified material weaknesses or deficiencies | N/A | N/A |
| Effectiveness | The Board, with the concurrence of the AC, is of the opinion that the Company's internal controls (including financial, operational, compliance, and information technology controls) and risk management systems were adequate and effective as at 31 December 2024 to address the risks that the Company considers relevant and material to its operations. | The Board, with the concurrence of the Audit Committee, is of the opinion that the Company's internal controls (including financial, operational, compliance, and information technology controls) and risk management systems were adequate and effective as at 31 December 2023 to address the risks that the Company considers relevant and material to its operations. |


# Section 6: Future Outlook

## S6.1: Strategic Direction

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Mergers and Acquisition | The Group is exploring merger and acquisition opportunities in Singapore, Malaysia, and China as part of its strategy for regional organic and inorganic growth. Additionally, on 6 November 2024, the Group acquired the business and assets of Veritas Dental Pte. Ltd. for a cash consideration of $800,000, enhancing its clinic network in Singapore. Furthermore, on 31 March 2025, the Group entered into a share purchase agreement to acquire the remaining 51% interest in EM2AI Pte. Ltd. for S$1,760,000. | In 2023, Q & M entered into a joint-venture agreement with EM2AI Professional Holdco Pte. Ltd., which involved an investment of S$1.6 million into the Group's subsidiary EM2AI Pte. Ltd. The agreement also included an interest-free loan of S$3.7 million for working capital purposes, resulting in the investor acquiring a 51% shareholding interest in EM2AI. This strategic move aims to strengthen the Group's financial position and improve cash flow while minimizing capital investment during EM2AI's growth stage. |
| New technologies | The Group is focused on AI and digital transformation, with plans to deploy AI-powered dental charting using OPG and digital intra-oral cameras across all clinics by the end of FY2025. Additionally, a binding agreement was signed with a major dental solutions provider to integrate EM2AI's dental AI solutions into their platform, expanding its reach to over 1,100 clinics across multiple countries. | The Group is focusing on advancing its technology initiatives, particularly in Artificial Intelligence (AI). It has developed AI-driven solutions such as the AI Guided Clinical Decision Support System (AI-GCDSS) and the cloud-based Integrated Dental Management System (EM2Clinic). Additionally, the Group's R&D division is prioritizing the advancement of PCR tests for infectious diseases and cancer, aiming for regulatory approvals and market launch to meet evolving healthcare needs. EM2AI has also rolled out AI X-Ray Dental Pathologies Detection and Automated Dental Charting systems across all Q & M clinics. |
| Organisational Restructuring | The Group is investing in talent management initiatives, including AI training for dentists to enhance diagnostic precision and effectiveness. The Q & M College of Dentistry achieved EduTrust Provisional Certification in March 2025, allowing for the enrollment of international students and enhancing the curriculum to keep dentists updated with the latest developments in dentistry. | In 2023, Q & M restructured its management by organizing area management teams that include dentists, nurses, operations, and finance personnel to enhance productivity and operational efficiencies across its dental clinics. Area Managers have been empowered to make improvements to work processes, which is part of the Group's strategy to maximize returns on a per-clinic basis and ensure that the geographical coverage of clinics aligns with emerging demand. |


## S6.2: Challenges and Uncertainties

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Economic challenges such as inflation, recession risks, and shifting consumer behavior that could impact revenue and profitability. | The company faces significant economic uncertainties, particularly related to the assessment of goodwill impairment, which is influenced by expected future market or economic conditions. Small changes in key assumptions regarding forecasted revenue growth and profit margins could lead to material adjustments in the carrying amounts of assets. Additionally, the assessment of income tax liabilities and the estimation of useful lives of property, plant, and equipment are subject to economic fluctuations and market conditions, which could materially impact financial outcomes in the next reporting year. | The macroeconomic conditions remain challenging due to geopolitical instability affecting both domestic and global growth in a high interest environment. There has been a widespread increase in interest rates and a significant rise in inflation, impacting the cost of goods and services for customers and suppliers. Management has considered the uncertain macroeconomic and geopolitical environment, which poses risks to revenue and profitability. |
| Competitive pressures from both established industry players and new, disruptive market entrants that the company faces. | The company is navigating competitive pressures from both established industry players and new entrants in the dental market. The strategic acquisition of Veritas Dental and the expansion of clinic locations indicate a response to competitive threats. Furthermore, the integration of AI-driven solutions and partnerships with educational institutions reflect efforts to enhance technological capabilities and maintain a competitive edge in the evolving dental healthcare landscape. | The Group faces competitive pressures from both established industry players and new entrants in the market. The introduction of advanced technologies, particularly in Artificial Intelligence, is reshaping the industry dynamics. The Group is focusing on leveraging AI to enhance its service offerings, but must navigate the competitive landscape where other players may also adopt similar technologies, potentially impacting its market position. |


## S6.3: Innovation and Development Plans

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| R&D investments, with a focus on advancing technology, improving products, and creating new solutions to cater to market trends | In FY2024, Q & M Dental Group focused on advancing technology through its investment in EM2AI, which secured medical device licenses for AI-driven diagnostic tools across Southeast Asia, enabling access to over 600 million people. The company also emphasized the integration of AI in clinical practices, training dentists to utilize AI-Clinical Decision Support Systems to enhance diagnostic precision. Specific R&D spending amounts were not disclosed in the report. | In 2023, Q & M Dental Group's R&D division focused on advancing their PCR tests for infectious diseases and cancer, aiming for regulatory approvals and market launch. The company made significant investments in artificial intelligence, particularly in developing an AI-guided clinical decision support system, which is expected to enhance diagnostic accuracy and treatment planning. The total R&D spending included an investment of S$1.6 million in a joint venture with EM2AI, aimed at strengthening their financial position and improving cash flow for further R&D activities. |
| New product launches, emphasizing the company's commitment to continuously introducing differentiated products | Q & M Dental Group launched several innovative products in FY2024, including AI-powered automated dental charting tools that utilize x-rays and intra-oral camera images. These tools are being deployed across clinics in Singapore and Malaysia, enhancing diagnostic capabilities and streamlining patient care. The company also introduced dental health reports generated through the Q & M App, marking a significant step in patient engagement and care delivery. | Q & M Dental Group launched several innovative products in 2023, including the AI-powered Guided Clinical Decision Support System (GCDSS) and the AI X-Ray Dental Pathologies Detection system. These products are designed to improve diagnostic speed and accuracy, thereby enhancing patient care. The GCDSS is currently being tested in selected outlets, with plans for a full rollout. Additionally, the Q & M Dental mobile app was launched in Malaysia, facilitating real-time appointment bookings and enhancing patient engagement. |
